Form 6-K PSYENCE BIOMEDICAL LTD. For: Jun 05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-41937
Psyence Biomedical Ltd.
(Translation of registrant’s name into English)
121
Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
EXPLANATORY NOTE
On May 4, 2026, the board of directors (the “Board”) of Psyence Biomedical Ltd. (the “Company”) approved a resolution to amend and restate the Psyence Biomedical Ltd. 2023 Equity Incentive Plan (the “Plan”) to correct a typographical error in Section 4(b).
The foregoing description of the amended and restated Plan (the “First Amended and Restated Plan”) does not purport to be complete and is qualified in its entirety by reference to the full text of the First Amended and Restated Plan, which is furnished as Exhibit 10.1 hereto and incorporated herein by reference.
1
EXHIBIT INDEX
| Exhibit No. | Description | |
| 10.1 | Psyence Biomedical Ltd. 2023 First Amended and Restated Equity Incentive Plan. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: June 5, 2026
| Psyence Biomedical Ltd. | ||
| By: | /s/ Warwick Corden-Lloyd | |
| Name: | Warwick Corden-Lloyd | |
| Title: | Chief Financial Officer | |
3
ATTACHMENTS / EXHIBITS
PSYENCE BIOMEDICAL LTD. 2023 FIRST AMENDED AND RESTATED EQUITY INCENTIVE PLAN